199 related articles for article (PubMed ID: 21132558)
1. Comparing the sensitivity of EQ-5D, SF-6D and 15D utilities to the specific effect of diabetic complications.
Kontodimopoulos N; Pappa E; Chadjiapostolou Z; Arvanitaki E; Papadopoulos AA; Niakas D
Eur J Health Econ; 2012 Feb; 13(1):111-20. PubMed ID: 21132558
[TBL] [Abstract][Full Text] [Related]
2. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
[TBL] [Abstract][Full Text] [Related]
3. Comparison of EQ-5D and SF-6D utilities in Pompe disease.
Kanters TA; Redekop WK; Kruijshaar ME; van der Ploeg AT; Rutten-van Mölken MP; Hakkaart L
Qual Life Res; 2015 Apr; 24(4):837-44. PubMed ID: 25342117
[TBL] [Abstract][Full Text] [Related]
4. Are condition-specific utilities more valid than generic preference-based ones in asthma? Evidence from a study comparing EQ-5D-3L and SF-6D with AQL-5D.
Kontodimopoulos N; Stamatopoulou E; Brinia A; Talias MA; Ferreira LN
Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):667-675. PubMed ID: 30048194
[TBL] [Abstract][Full Text] [Related]
5. Comparing and explaining differences in the magnitude, content, and sensitivity of utilities predicted by the EQ-5D, SF-6D, HUI 3, 15D, QWB, and AQoL-8D multiattribute utility instruments.
Richardson J; Khan MA; Iezzi A; Maxwell A
Med Decis Making; 2015 Apr; 35(3):276-91. PubMed ID: 25159172
[TBL] [Abstract][Full Text] [Related]
6. Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the Cancer Care Outcomes Research and Surveillance (CanCORS) study.
Tramontano AC; Schrag DL; Malin JK; Miller MC; Weeks JC; Swan JS; McMahon PM
Med Decis Making; 2015 Apr; 35(3):371-87. PubMed ID: 25670839
[TBL] [Abstract][Full Text] [Related]
7. Comparing SF-6D and EQ-5D utilities across groups differing in health status.
Kontodimopoulos N; Pappa E; Papadopoulos AA; Tountas Y; Niakas D
Qual Life Res; 2009 Feb; 18(1):87-97. PubMed ID: 19051058
[TBL] [Abstract][Full Text] [Related]
8. The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure.
Kontodimopoulos N; Argiriou M; Theakos N; Niakas D
Eur J Health Econ; 2011 Aug; 12(4):383-91. PubMed ID: 20473544
[TBL] [Abstract][Full Text] [Related]
9. Comparison of EQ-5D and SF-6D utilities in mental health patients.
Lamers LM; Bouwmans CA; van Straten A; Donker MC; Hakkaart L
Health Econ; 2006 Nov; 15(11):1229-36. PubMed ID: 16625671
[TBL] [Abstract][Full Text] [Related]
10. Relationship Between the Wisconsin Stone Quality of Life (WISQOL) and Preference-Based/Health Utility Measures of Health-Related Quality of Life (HRQoL) in Kidney Stone Patients.
Polotti C; Tan B; Borglum N; Olweny EO
Urology; 2020 Jul; 141():33-38. PubMed ID: 32305539
[TBL] [Abstract][Full Text] [Related]
11. Health state utility instruments compared: inquiring into nonlinearity across EQ-5D-5L, SF-6D, HUI-3 and 15D.
Gamst-Klaussen T; Chen G; Lamu AN; Olsen JA
Qual Life Res; 2016 Jul; 25(7):1667-78. PubMed ID: 26687615
[TBL] [Abstract][Full Text] [Related]
12. Discriminative validity of the EQ-5D-5 L and SF-12 in older adults with arthritis.
Tawiah AK; Al Sayah F; Ohinmaa A; Johnson JA
Health Qual Life Outcomes; 2019 Apr; 17(1):68. PubMed ID: 30995930
[TBL] [Abstract][Full Text] [Related]
13. Comparison of utility measures and their relationship with other health status measures in 1041 patients with rheumatoid arthritis.
Lillegraven S; Kristiansen IS; Kvien TK
Ann Rheum Dis; 2010 Oct; 69(10):1762-7. PubMed ID: 20448285
[TBL] [Abstract][Full Text] [Related]
14. Comparison of preference-based utilities of the 15D, EQ-5D and SF-6D in patients with HIV/AIDS.
Stavem K; Frøland SS; Hellum KB
Qual Life Res; 2005 May; 14(4):971-80. PubMed ID: 16041894
[TBL] [Abstract][Full Text] [Related]
15. The responsiveness of quality of life utilities to change in depression: a comparison of instruments (SF-6D, EQ-5D, and DFD).
Gerhards SA; Huibers MJ; Theunissen KA; de Graaf LE; Widdershoven GA; Evers SM
Value Health; 2011; 14(5):732-9. PubMed ID: 21839412
[TBL] [Abstract][Full Text] [Related]
16. Quality-adjusted life expectancies in patients with rheumatoid arthritis--comparison of index scores from EQ-5D, 15D, and SF-6D.
Sørensen J; Linde L; Ostergaard M; Hetland ML
Value Health; 2012; 15(2):334-9. PubMed ID: 22433765
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life and health utilities in insulin-treated type 2 diabetes: the impact of related comorbidities/complications.
Yfantopoulos J; Chantzaras A
Eur J Health Econ; 2020 Jul; 21(5):729-743. PubMed ID: 32128637
[TBL] [Abstract][Full Text] [Related]
18. An empirical evaluation of the SF-12, SF-6D, EQ-5D and Michigan Hand Outcome Questionnaire in patients with rheumatoid arthritis of the hand.
Dritsaki M; Petrou S; Williams M; Lamb SE
Health Qual Life Outcomes; 2017 Jan; 15(1):20. PubMed ID: 28118833
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD).
Yang F; Lau T; Lee E; Vathsala A; Chia KS; Luo N
Eur J Health Econ; 2015 Dec; 16(9):1019-26. PubMed ID: 25519850
[TBL] [Abstract][Full Text] [Related]
20. Interchangeability of the EQ-5D and the SF-6D, and comparison of their psychometric properties in a spinal postoperative Spanish population.
Selva-Sevilla C; Ferrara P; Gerónimo-Pardo M
Eur J Health Econ; 2020 Jun; 21(4):649-662. PubMed ID: 32065301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
